Glycopyrronium Martindale: Uses, Dosage & Side Effects
An anticholinergic (antimuscarinic) injection used in perioperative care to reduce secretions, prevent bradycardia, and counteract the muscarinic effects of neostigmine during reversal of neuromuscular blockade
Glycopyrronium Martindale contains the active substance glycopyrronium bromide, a synthetic quaternary ammonium anticholinergic (antimuscarinic) agent widely used in perioperative medicine. This hospital-administered injection serves three primary clinical purposes: reducing salivary and gastric secretions before surgery, preventing or treating bradycardia (abnormally slow heart rate) during anesthesia, and counteracting the unwanted muscarinic side effects of acetylcholinesterase inhibitors such as neostigmine when these are used to reverse neuromuscular blockade after surgery. Glycopyrronium bromide is included on the WHO Model List of Essential Medicines, reflecting its fundamental importance in safe anesthetic practice worldwide.
Quick Facts: Glycopyrronium Martindale
Key Takeaways
- Glycopyrronium Martindale is a quaternary ammonium anticholinergic that does not readily cross the blood-brain barrier, resulting in fewer central nervous system side effects (confusion, hallucinations) compared with atropine.
- It is primarily used in hospital settings for three purposes: preoperative reduction of secretions, prevention of intraoperative bradycardia, and protection against the muscarinic side effects of neostigmine during reversal of neuromuscular blockade.
- The drug must not be used in patients with narrow-angle glaucoma, myasthenia gravis, prostatic hypertrophy with urinary retention, paralytic ileus, or severe ulcerative colitis.
- Glycopyrronium bromide is included on the WHO Model List of Essential Medicines and is considered a cornerstone of safe perioperative anticholinergic therapy worldwide.
- Special caution is required in elderly patients, children, patients with Down syndrome, and those with cardiovascular disease, as they may be more sensitive to its effects on heart rate and secretory function.
What Is Glycopyrronium Martindale and What Is It Used For?
Glycopyrronium Martindale contains the active substance glycopyrronium bromide (also known internationally as glycopyrrolate), which belongs to a class of medications called anticholinergics or antimuscarinics. These drugs work by competitively blocking the action of acetylcholine, a neurotransmitter that activates muscarinic receptors throughout the body. Muscarinic receptors are found in many organs and tissues, including salivary glands, the gastrointestinal tract, the heart, and the smooth muscle of the airways. By blocking these receptors, glycopyrronium reduces secretions, relaxes smooth muscle, and increases heart rate.
What makes glycopyrronium bromide particularly valuable in clinical practice is its chemical structure as a quaternary ammonium compound. Unlike tertiary amine anticholinergics such as atropine and hyoscine (scopolamine), glycopyrronium carries a permanent positive charge that prevents it from easily crossing the blood-brain barrier. This means it produces significantly fewer central nervous system side effects such as drowsiness, confusion, restlessness, and hallucinations. This property makes glycopyrronium the preferred anticholinergic agent in many perioperative protocols, particularly for elderly patients who are more susceptible to central anticholinergic effects.
Glycopyrronium Martindale is specifically formulated as a sterile solution for injection, available in glass ampoules containing either 1 mL (200 micrograms) or 3 mL (600 micrograms) of glycopyrronium bromide. The solution can be administered intravenously (directly into a vein) or intramuscularly (into a muscle), depending on the clinical situation and desired speed of onset. When given intravenously, the cardiovascular effects begin within approximately 1 minute, while the antisecretory effects take 15 to 30 minutes to reach their peak. The antisecretory action is notably long-lasting, persisting for up to 7 hours after a single dose.
The primary clinical indications for Glycopyrronium Martindale in perioperative medicine are:
- Reversal of neuromuscular blockade: During surgery, patients often receive neuromuscular blocking agents (muscle relaxants) to facilitate intubation and surgical access. At the end of surgery, acetylcholinesterase inhibitors such as neostigmine or pyridostigmine are administered to reverse the paralysis. However, these drugs also stimulate muscarinic receptors throughout the body, causing unwanted effects including bradycardia (dangerous slowing of the heart), excessive salivation, bronchospasm, increased bowel motility, and miosis. Glycopyrronium is given alongside neostigmine to block these muscarinic effects while allowing the desired nicotinic (neuromuscular) reversal to proceed. This is the most common use of glycopyrronium in modern anesthetic practice.
- Preoperative medication (premedication): Glycopyrronium may be administered before anesthesia to reduce the volume of salivary, tracheobronchial, and gastric secretions. This is particularly important during airway procedures, oral or dental surgery, and in situations where excessive secretions could compromise airway management. Reducing gastric acid volume and acidity also provides some protection against aspiration pneumonitis should regurgitation occur during anesthesia.
- Intraoperative bradycardia: Certain surgical maneuvers, particularly those involving traction on the peritoneum, manipulation of the eye (oculocardiac reflex), or stimulation of the vagus nerve, can trigger reflex bradycardia that may compromise cardiac output and blood pressure. Glycopyrronium can be administered intraoperatively to prevent or treat such episodes by blocking vagal input to the sinoatrial node of the heart.
Beyond the injectable formulation, glycopyrronium bromide is also available as an inhalation powder (marketed as Seebri Breezhaler) for the maintenance treatment of chronic obstructive pulmonary disease (COPD). In this formulation, the drug acts as a long-acting muscarinic antagonist (LAMA) that relaxes airway smooth muscle and reduces mucus secretion in the lungs. However, Glycopyrronium Martindale specifically refers to the injectable formulation used in perioperative settings, and this article focuses primarily on that indication.
Glycopyrronium offers several advantages over atropine as a perioperative anticholinergic: (1) it does not cross the blood-brain barrier, so it causes less confusion and sedation; (2) it is a more potent antisecretory agent with longer duration of action; (3) it produces less tachycardia (rapid heart rate) at equipotent antisecretory doses; (4) it causes less mydriasis (pupil dilation) and cycloplegia (loss of near-focus ability); and (5) when given with neostigmine, it provides a more stable heart rate profile with less initial tachycardia followed by bradycardia. For these reasons, glycopyrronium has largely replaced atropine as the standard anticholinergic in many anesthetic departments worldwide.
What Should You Know Before Receiving Glycopyrronium Martindale?
Contraindications
There are several conditions in which Glycopyrronium Martindale must not be used. These absolute contraindications reflect situations where the anticholinergic effects of the drug could cause serious harm.
- Hypersensitivity: Do not receive this medication if you are allergic to glycopyrronium bromide or any of the other ingredients (sodium chloride, hydrochloric acid, water for injections).
- Narrow-angle glaucoma: Anticholinergic agents can increase intraocular pressure by causing pupil dilation and blocking the drainage of aqueous humor. In patients with narrow-angle (closed-angle) glaucoma, this can trigger an acute glaucoma attack with severe eye pain, vision loss, and potential permanent damage.
- Myasthenia gravis: This autoimmune neuromuscular disease causes muscle weakness. Anticholinergics can worsen muscle weakness and interfere with the cholinergic medications (such as pyridostigmine) used to manage the condition.
- Prostatic hypertrophy with urinary retention: Glycopyrronium relaxes the detrusor muscle of the bladder and increases sphincter tone, which can worsen urinary retention in patients with an enlarged prostate gland.
- Gastrointestinal obstruction or paralytic ileus: By reducing gastrointestinal motility, glycopyrronium can worsen intestinal obstruction and potentially lead to dangerous complications including perforation.
- Severe ulcerative colitis or toxic megacolon: Reduced gut motility can precipitate toxic megacolon, a life-threatening complication of inflammatory bowel disease.
- Prolonged QT interval (when combined with neostigmine): The combination of glycopyrronium and neostigmine should be avoided in patients with prolonged QT interval on electrocardiography, as this may increase the risk of serious cardiac arrhythmias.
Warnings and Precautions
Patients with Down syndrome may be unusually sensitive to the effects of anticholinergic drugs, particularly on heart rate and pupil dilation. Elderly patients (over 60 years) are more susceptible to anticholinergic side effects including confusion, urinary retention, and constipation. Children may be more sensitive to the temperature-regulating effects of the drug. Careful dose adjustment and monitoring are essential in these groups.
Before and during treatment with Glycopyrronium Martindale, inform your doctor or anesthesiologist if any of the following conditions apply to you:
- Cardiovascular disease: Patients with coronary artery disease, heart failure, cardiac arrhythmias, or hypertension require close monitoring. Glycopyrronium can increase heart rate, which may be harmful in patients with ischemic heart disease. In patients undergoing cardiac surgery, changes in heart rate may be particularly significant.
- Hyperthyroidism: Patients with an overactive thyroid gland already have an elevated resting heart rate and may experience an exaggerated tachycardic response to anticholinergic drugs.
- High fever: Glycopyrronium inhibits sweating, which is the body’s primary mechanism for dissipating heat. In febrile patients, particularly children, this can impair thermoregulation and potentially lead to dangerous hyperthermia.
- Gastroesophageal reflux disease (GERD): Anticholinergic drugs reduce lower esophageal sphincter tone, which can worsen acid reflux symptoms and increase the risk of aspiration.
- Diarrhea: While anticholinergics reduce gut motility and can help control diarrhea, they may mask underlying serious conditions such as incomplete intestinal obstruction.
- Renal impairment: Glycopyrronium bromide is primarily excreted by the kidneys. In patients with impaired kidney function, the drug may accumulate, leading to prolonged and intensified effects. The doctor may need to reduce the dose or extend the dosing interval.
- Inhaled anesthetics: Certain volatile anesthetic agents (halogenated hydrocarbons such as halothane) can sensitize the heart to the arrhythmogenic effects of anticholinergic drugs. The anesthesiologist will take this into account when planning the anesthetic technique.
- Recent myocardial infarction: Patients who have recently suffered a heart attack require particular caution, as changes in heart rate can increase myocardial oxygen demand and potentially worsen ischemia.
Pregnancy and Breastfeeding
The safety of Glycopyrronium Martindale during pregnancy has not been fully established through controlled clinical studies. Animal reproductive toxicity studies are limited. The drug should only be used during pregnancy if the expected clinical benefit justifies the potential risk to the fetus. In practice, the decision to use glycopyrronium during pregnancy is typically made by the anesthesiologist in the context of essential surgical procedures where the benefit of anticholinergic cover clearly outweighs the theoretical risk.
It is not known whether glycopyrronium bromide is excreted in human breast milk. However, as a quaternary ammonium compound with poor lipid solubility, significant transfer into breast milk is considered unlikely. Nevertheless, caution should be exercised when administering glycopyrronium to breastfeeding mothers, and a risk-benefit assessment should be made by the treating physician.
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor or anesthesiologist before receiving this medication.
Driving and Operating Machinery
Glycopyrronium Martindale can cause blurred vision, dizziness, and other effects that may impair your ability to drive or operate machinery safely. Do not drive or use machines until these symptoms have completely resolved. While glycopyrronium causes fewer central nervous system effects than atropine due to its limited blood-brain barrier penetration, peripheral effects on vision and coordination can still affect driving ability. In practice, patients receiving glycopyrronium as part of surgical care will typically be advised not to drive for at least 24 hours after general anesthesia regardless of the specific medications used.
Important Information About Ingredients
Glycopyrronium Martindale contains less than 1 mmol of sodium (23 mg) per 2 mL ampoule, meaning it is essentially sodium-free. This is important information for patients on a sodium-restricted diet, although the clinical significance of the sodium content in an injectable perioperative medication is minimal.
How Does Glycopyrronium Martindale Interact with Other Drugs?
Drug interactions with Glycopyrronium Martindale primarily involve pharmacodynamic interactions, where the anticholinergic effects of glycopyrronium are enhanced or opposed by other medications. Understanding these interactions is critical for safe perioperative care, as patients frequently receive multiple medications during the surgical period. Always inform your doctor or anesthesiologist about all medications you are currently taking, including prescription medicines, over-the-counter products, herbal supplements, and recreational substances.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Tricyclic antidepressants (e.g., amitriptyline, imipramine) | Additive anticholinergic effects: increased risk of dry mouth, constipation, urinary retention, tachycardia, confusion | Monitor closely; may require dose reduction |
| MAO inhibitors (e.g., phenelzine, tranylcypromine) | Enhanced anticholinergic effects and potential for unpredictable cardiovascular responses | Use with caution; close hemodynamic monitoring |
| Clozapine | Potentiation of anticholinergic side effects; increased risk of ileus and urinary retention | Avoid combination if possible; monitor gastrointestinal function |
| Phenothiazines (e.g., chlorpromazine, prochlorperazine) | Additive anticholinergic and sedative effects | Monitor for excessive anticholinergic burden |
| Sympathomimetics (common in cold and cough preparations) | Additive increase in heart rate when used concurrently | Monitor heart rate; inform anesthesiologist of recent use |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Domperidone / Metoclopramide | Glycopyrronium opposes the prokinetic (gut motility-enhancing) effects of these drugs | Reduced antiemetic efficacy; consider alternative antiemetics |
| Antihistamines (e.g., promethazine, diphenhydramine) | Additive anticholinergic effects including sedation and dry mouth | Monitor; generally manageable in perioperative setting |
| Sublingual glyceryl trinitrate (nitroglycerin) | Drug-induced dry mouth may impede dissolution of sublingual tablets | Advise patients; consider spray formulation if GTN needed |
| Slow-dissolving digoxin tablets | Reduced gut motility may increase digoxin absorption from slow-dissolving formulations | Monitor digoxin levels if concurrent use is prolonged |
| Corticosteroids (e.g., prednisolone) | Anticholinergics may increase intraocular pressure; corticosteroids have similar potential | Monitor intraocular pressure in susceptible patients |
| Levodopa / Amantadine | Additive anticholinergic effects; potential for increased confusion in Parkinson’s patients | Use with caution; monitor neurological status |
| Ketoconazole | Decreased absorption of ketoconazole due to reduced gastric acidity caused by glycopyrronium | Separate administration times if possible |
| Nefopam | Additive anticholinergic effects including tachycardia and dry mouth | Monitor heart rate when used together postoperatively |
In the perioperative context, the most important interaction to understand is the deliberate co-administration of glycopyrronium with neostigmine. When neostigmine is given to reverse neuromuscular blockade, it inhibits acetylcholinesterase at both nicotinic receptors (at the neuromuscular junction, producing the desired muscle recovery) and muscarinic receptors (throughout the body, producing unwanted side effects). Glycopyrronium is specifically given to block the muscarinic effects while allowing the nicotinic effects to proceed. The two drugs can be mixed in the same syringe and administered simultaneously, which is common clinical practice.
The advantage of glycopyrronium over atropine in this context is its more favorable heart rate profile. When atropine is given with neostigmine, the initial rapid onset of atropine’s vagolytic effect causes tachycardia, followed by a period of relative bradycardia as atropine wears off while neostigmine’s muscarinic effects persist. Glycopyrronium, with its slower onset and longer duration of vagal blockade, provides a more stable heart rate throughout the reversal period.
What Is the Correct Dosage of Glycopyrronium Martindale?
Glycopyrronium Martindale is always administered by a doctor, anesthesiologist, or nurse in a hospital or clinical setting. It can be given as an intravenous injection (into a vein) or an intramuscular injection (into a muscle). Intravenous administration provides a faster onset of action and is preferred in most acute situations. The dose is tailored to the individual patient based on body weight, age, clinical indication, and the patient’s general health status.
Preoperative Dose – Adults
Adults and Adolescents Over 12 Years
Dose: 200 to 400 micrograms (0.2 to 0.4 mg) given intravenously or intramuscularly before anesthesia is induced.
Alternative weight-based dosing: 4 to 5 micrograms per kilogram of body weight (0.004 to 0.005 mg/kg), up to a maximum of 400 micrograms (0.4 mg).
Timing: Administered 30–60 minutes before induction of anesthesia when given intramuscularly, or immediately before induction when given intravenously.
Preoperative Dose – Children
Children Under 12 Years
Dose: 4 to 8 micrograms per kilogram of body weight (0.004 to 0.008 mg/kg) given intravenously or intramuscularly before anesthesia.
Maximum single dose: 200 micrograms (0.2 mg).
Note: Children may require higher weight-based doses than adults due to their relatively larger body surface area and faster drug metabolism. However, the absolute maximum dose should not be exceeded.
Intraoperative Dose
Adults and Adolescents Over 12 Years
Dose: 200 to 400 micrograms (0.2 to 0.4 mg) given intravenously as a single dose. Alternatively, 4 to 5 micrograms/kg (up to 400 micrograms maximum).
Repeat doses: May be repeated as clinically required to manage bradycardia or excessive secretions during the procedure.
Children Under 12 Years
Dose: 4 to 8 micrograms per kilogram of body weight (0.004 to 0.008 mg/kg) given intravenously, up to a maximum of 200 micrograms (0.2 mg).
Repeat doses: May be repeated as clinically required.
Reversal of Neuromuscular Blockade
Adults and Adolescents Over 12 Years
Dose: 200 micrograms (0.2 mg) of glycopyrronium per 1,000 micrograms (1 mg) of neostigmine, given intravenously.
Alternative weight-based dosing: 10 to 15 micrograms per kilogram (0.01 to 0.015 mg/kg) given intravenously alongside neostigmine at 50 micrograms per kilogram (0.05 mg/kg), or an equivalent dose of pyridostigmine.
Administration: Glycopyrronium may be mixed in the same syringe as neostigmine or pyridostigmine and administered simultaneously.
Children
Dose: 10 micrograms per kilogram (0.01 mg/kg) given intravenously alongside neostigmine at 50 micrograms per kilogram (0.05 mg/kg), or an equivalent dose of pyridostigmine.
Administration: May be given in the same syringe as neostigmine or pyridostigmine.
Elderly Patients
Elderly patients (over 60 years of age) may be more sensitive to the cardiovascular and anticholinergic effects of glycopyrronium. While no specific dose reduction is mandated, careful dose selection at the lower end of the recommended range is advisable. Elderly patients should be monitored closely for tachycardia, urinary retention, confusion, and constipation. The duration of action may also be prolonged in elderly patients due to age-related changes in renal clearance.
Renal Impairment
Glycopyrronium bromide is primarily excreted by the kidneys. In patients with significant renal impairment, the drug may accumulate with repeated dosing, leading to prolonged and potentially intensified anticholinergic effects. Repeated or large doses should be avoided in patients with impaired kidney function. The treating physician will assess kidney function and adjust the dosing regimen accordingly.
Overdose
Overdose with glycopyrronium is unlikely in clinical practice because the drug is administered by healthcare professionals who carefully calculate and verify each dose. However, should an overdose occur, symptoms would reflect exaggerated anticholinergic effects: severe dry mouth, extreme thirst, dilated pupils with inability to focus, flushed and hot skin, high fever (particularly in children due to inhibition of sweating), rapid heart rate, difficulty urinating, and reduced bowel sounds. In severe cases, respiratory depression, coma, and cardiovascular collapse may occur. Treatment is supportive and may include the administration of physostigmine (a cholinesterase inhibitor that crosses the blood-brain barrier) under specialist supervision if severe central anticholinergic toxicity is present.
What Are the Side Effects of Glycopyrronium Martindale?
Like all medicines, Glycopyrronium Martindale can cause side effects, although not everybody experiences them. The side effects are largely predictable from the drug’s anticholinergic (antimuscarinic) mechanism of action – they result from blocking acetylcholine at muscarinic receptors in various organs throughout the body. Most side effects are mild to moderate in severity and resolve once the drug’s effects wear off. However, some side effects can be serious and require immediate medical attention.
Contact a doctor or nurse immediately if you experience swelling of the face, lips, or throat that makes it difficult to swallow or breathe, along with itching and rash. These may be signs of a serious allergic reaction (anaphylaxis) or angioedema. Although the exact frequency is unknown, these reactions can be life-threatening and require emergency treatment.
Very Common
May affect more than 1 in 10 people
- Dry mouth (xerostomia) – the most frequently reported side effect, resulting from reduced salivary gland secretion
Common
May affect up to 1 in 10 people
- Drowsiness (somnolence)
- Visual disturbances (blurred vision, difficulty focusing)
- Altered heart rate – tachycardia (fast heartbeat) or irregular heartbeat
- Urinary urgency with inability to empty the bladder (urinary retention)
Very Rare
May affect up to 1 in 10,000 people
- Elevated intraocular pressure (glaucoma) – may present as eye pain, visual halos, and reduced vision
Not Known
Frequency cannot be estimated from available data
- Bradycardia (slow heart rate) – may occur briefly at lower doses before the vagolytic effect predominates
- Confusion – more common in elderly patients
- Increased urinary frequency
- Nausea and vomiting
- Dizziness
- Flushing and dry skin
- Dilated pupils (mydriasis) and difficulty focusing (cycloplegia)
- Photophobia (discomfort from bright light)
- Constipation
- Decreased sweating (anhidrosis) – may impair thermoregulation, particularly in children and in hot environments
- Reduced bronchial secretions
- Anaphylaxis/angioedema – serious allergic reaction requiring emergency treatment
It is important to understand that many of the side effects listed above are, in fact, the desired therapeutic effects of the drug when used in specific clinical contexts. For example, the drying of secretions (dry mouth, reduced bronchial secretions) is the intended effect when glycopyrronium is used as preoperative medication. Similarly, the increase in heart rate is the desired outcome when the drug is used to treat intraoperative bradycardia. The clinical team will monitor you for these effects and manage them as part of your overall perioperative care.
Elderly patients are particularly vulnerable to certain side effects, including confusion, urinary retention, and constipation. Patients with pre-existing conditions such as prostatic hypertrophy, chronic constipation, or cognitive impairment should be monitored with particular care. In pediatric patients, the most concerning potential side effect is impaired thermoregulation due to reduced sweating, especially in warm environments or in the presence of fever.
If you experience any side effects, including those not listed here, tell your doctor or nurse. You can also report side effects to your national medicines regulatory authority (for example, the MHRA in the UK, EMA in the EU, or FDA in the US). By reporting side effects, you help provide valuable information about the safety of this medicine.
How Should Glycopyrronium Martindale Be Stored?
Glycopyrronium Martindale should be stored out of the sight and reach of children at all times. There are no special temperature storage requirements for this product – it can be kept at room temperature. However, it should be protected from direct sunlight and excessive heat.
The solution should not be used after the expiry date printed on the ampoule label and outer carton. The expiry date refers to the last day of that month. Once an ampoule has been opened, the medication should be used immediately and any remaining solution must be discarded. This is because the product does not contain preservatives, and microbiological contamination cannot be excluded once the ampoule is opened.
Before use, visually inspect the solution. It should be clear and colorless. Do not use the medication if you notice any particles in the solution, if the solution is discolored, or if the glass ampoule appears to be damaged or cracked. Any unused medicine or waste material should be disposed of in accordance with local pharmaceutical waste disposal requirements. Medicines should not be disposed of via household waste or wastewater.
What Does Glycopyrronium Martindale Contain?
The active ingredient in Glycopyrronium Martindale is glycopyrronium bromide (also known as glycopyrrolate in some countries). The concentration of the solution is 200 micrograms per milliliter (0.2 mg/mL).
- 1 mL ampoule: Contains 200 micrograms of glycopyrronium bromide
- 3 mL ampoule: Contains 600 micrograms of glycopyrronium bromide
The other ingredients (excipients) are:
- Sodium chloride: Added to make the solution isotonic (matching the body’s natural salt concentration) for comfortable injection
- Hydrochloric acid: Used to adjust the pH of the solution to an appropriate level for injection
- Water for injections: The sterile solvent that forms the base of the solution
Glycopyrronium Martindale is a clear, colorless solution for injection. It is supplied in glass ampoules and is available in packs of 10 ampoules. The 1 mL ampoules are suitable for single-dose use in adults and older children, while the 3 mL ampoules provide a larger volume that can be drawn up in precise amounts as needed.
The marketing authorization for Glycopyrronium Martindale is held by Ethypharm (Saint-Cloud, France). The product is manufactured by Martindale Pharma (Romford, Essex, United Kingdom) and Ethypharm (Grand Quevilly and Châteauneuf-en-Thymerais, France).
Frequently Asked Questions
Glycopyrronium bromide and atropine are both anticholinergic (antimuscarinic) drugs, but they differ in important ways. Glycopyrronium is a quaternary ammonium compound that does not easily cross the blood-brain barrier, so it causes far fewer central nervous system side effects such as confusion, drowsiness, and hallucinations. Atropine is a tertiary amine that freely enters the brain and can cause these effects. Glycopyrronium is also a more potent and longer-lasting antisecretory agent (reducing saliva and bronchial secretions) and produces less tachycardia (rapid heart rate) at equivalent antisecretory doses. When used with neostigmine to reverse neuromuscular blockade, glycopyrronium provides a more stable heart rate than atropine. For these reasons, glycopyrronium has become the preferred anticholinergic in many anesthetic departments worldwide.
While Glycopyrronium Martindale (the injectable formulation) is specifically indicated for perioperative use, glycopyrronium bromide in oral formulations is used off-label or with specific product approvals in some countries for the management of hyperhidrosis (excessive sweating) and sialorrhea (excessive drooling or salivation). Oral glycopyrronium tablets or solutions are prescribed for drooling in children and adults with neurological conditions such as cerebral palsy. A topical formulation of glycopyrronium (glycopyrronium tosylate, marketed as Qbrexza in the US) is specifically approved for treating primary axillary hyperhidrosis (excessive underarm sweating). These uses leverage the same antisecretory mechanism but require different formulations and dosing regimens than the injectable product discussed in this article.
During surgery, muscle relaxant drugs (neuromuscular blocking agents) are used to paralyze muscles and facilitate the surgical procedure. At the end of surgery, neostigmine is given to reverse this paralysis by increasing acetylcholine levels at the neuromuscular junction. However, neostigmine also increases acetylcholine at muscarinic receptors throughout the body, causing unwanted effects including dangerous slowing of the heart (bradycardia), excessive saliva production, bronchospasm (airway narrowing), increased bowel motility, and miosis (pupil constriction). Glycopyrronium is given at the same time to block these unwanted muscarinic effects while allowing the beneficial effect at the neuromuscular junction to proceed. The two drugs can be mixed in the same syringe and injected together, which is standard practice in most operating theaters.
Glycopyrronium bromide requires caution in patients with impaired kidney function. The drug is primarily eliminated through the kidneys – approximately 65–80% of a dose is excreted unchanged in the urine. In patients with reduced kidney function, this clearance is impaired, which means the drug may accumulate in the body if repeated or large doses are given. Accumulation can lead to prolonged and intensified anticholinergic effects, including tachycardia, dry mouth, urinary retention, and potentially confusion. For patients with renal impairment, doctors will typically use the lowest effective dose, extend the interval between doses if multiple administrations are needed, and monitor more closely for signs of excessive anticholinergic activity. A single dose for a specific indication (such as reversal of neuromuscular blockade) is generally well tolerated even in patients with moderate renal impairment.
The duration of action depends on the specific effect. After intravenous administration, the cardiovascular effects (increased heart rate, vagal blockade) last approximately 2–3 hours. The antisecretory effects (drying of saliva, bronchial, and gastric secretions) are notably longer-lasting, persisting for up to 7 hours after a single dose. This extended antisecretory duration is one of the clinical advantages of glycopyrronium over atropine, which has a shorter antisecretory effect. The elimination half-life of glycopyrronium from the blood is relatively short at approximately 0.6–1.2 hours, but the pharmacological effects outlast the measurable blood levels because the drug binds tightly to muscarinic receptors. In patients with kidney impairment, the duration of all effects may be prolonged due to reduced clearance.
Before receiving glycopyrronium, you should tell your anesthesiologist about: (1) all medications you are currently taking, including over-the-counter drugs, herbal remedies, and supplements – particularly antidepressants, antipsychotics, antihistamines, or Parkinson’s disease medications; (2) any known allergies, especially to medications; (3) any history of eye problems, particularly glaucoma; (4) any prostate problems or difficulty urinating; (5) any heart conditions, including irregular heartbeat, coronary artery disease, or recent heart attack; (6) any thyroid problems; (7) any kidney or liver disease; (8) if you have Down syndrome; (9) if you are pregnant, breastfeeding, or planning to become pregnant; and (10) any previous problems with anesthesia or anticholinergic medications. This information helps your anesthesiologist choose the safest medications and doses for your procedure.
References
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- British National Formulary (BNF). Glycopyrronium bromide. National Institute for Health and Care Excellence (NICE); 2025.
- European Medicines Agency (EMA). Glycopyrronium bromide – Summary of Product Characteristics. EMA; 2024.
- Mirakhur RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. Anaesthesia. 1983;38(12):1195-1204.
- Sasada M, Smith S. Drugs in Anaesthesia and Intensive Care. 5th ed. Oxford University Press; 2022.
- European Society of Anaesthesiology and Intensive Care (ESAIC). Guidelines on perioperative medication management. European Journal of Anaesthesiology. 2024;41(3):175-220.
- Ali-Melkkilä T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiologica Scandinavica. 1993;37(7):633-642.
- Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. Clinical Pharmacology and Therapeutics. 1980;28(1):78-81.
- Camu F, d’Hollander A. Neostigmine-glycopyrrolate and neostigmine-atropine combinations for the reversal of pancuronium neuromuscular blockade. Acta Anaesthesiologica Belgica. 1981;32(3):175-183.
- U.S. Food and Drug Administration (FDA). Glycopyrrolate Injection – Prescribing Information. FDA; 2023.
Medical Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – Specialists in Anesthesiology, Perioperative Medicine, and Clinical Pharmacology
Medical Review
Reviewed by iMedic Medical Review Board – Independent panel following WHO, EMA, BNF, and ESAIC guidelines
Evidence Standard
Level 1A: Based on systematic reviews, meta-analyses, and established international clinical guidelines (GRADE framework)
Editorial Independence
No commercial funding. No pharmaceutical sponsorship. All content is independently produced and reviewed.
Last medical review: | Published: